R&D Making The World Healthier THROUGH INNOVATION

    주요기술 소개

    Natural Drug

    Established new drug development system for herbal and drugs derived
    from natural materials,
    Drug delivery system (DDS)
    research is on going

    What are new drugs derived from natural products?
    It is a new medicinal product that uses natural products, which collectively refers to plants, animals, minerals, microorganisms and their metabolites obtained from nature.

    Technology Introduction

    NLRP3 Inflammasome inhibitor BTK inhibitor

    NLRP3 Inflammasome

    (It plays a major role in IL-1ß, IL-18 expression, which is an inflammation inducer.)

    • Inflammasome is a complex protein that activates caspase-1 and consists of the following three proteins
      1. 1) the sensor protein NLRP3 (NOD-like receptor family, pyrin domain-containing 3),
      2. 2) an adapter protein, an ASC (apoptosis-associated speck-like protein containing a caspase-recruitment domain) and
      3. 3) Effect protein pro-caspase-1
    • The constituents of the Inflammasome are assembled when microbial infection or tissue injury occurs. Inflammasome is assembled and activated in the cytosol and activates caspase-1 to secrete IL-1β or IL-18 to perform innate immunity defense function of host
    • Based on this mechanism, inhibition of the formation of NLRs or ASC and inflammatory complexes is considered as a potential treatment for diseases mediated by these proteins

    MDB-7103

    NASH

    Non-alcoholic steatohepatitis

    Nonalcoholic Steatohepatitis(NASH)

    • Most common chronic liver disease(non-alcoholic fatty liver disease, NAFLD) and is closely related to type 2 diabetes, obesity and metabolic syndrome.
    • Due to westernized eating habits, obesity and diabetes, the number of nonalcoholic fatty liver disease patients is rapidly increasing in Korea.
    • Nonalcoholic fatty liver disease is a disease of the non-alcoholic fatty liver before it develops into cirrhosis. Liver tissues are inflamed in this status.
    Causes
    • As a first hit with insulin resistance, fat accumulates in the hepatocytes, resulting in simple fatty liver.
    • Oxidative stress is induced and hyperpigmentation of lipid peroxidation and inflammatory cytokines results in the addition of a second hit, resulting in hepatocyte injury and inflammatory reaction leading to lipid hepatitis
    Market / Research Status
    • No NASH treatment currently available
    • Market size is estimated to be $ 3.3 billion in 2020 and be expected $ 20.6 billion by 2025
    • Currently more than 50 clinical trials are underway worldwide.
    • The association between NLRP3 inflammasome activation and nonalcoholic steatohepatitis has been revealed, and global pharmaceutical companies are working on the development of therapeutic drugs
    Development Status
    • Mass production system for therapeutic raw materials is established, Collaborative research with specialized research institutes
    • In animal models, efficacy equal to or better than the control group was confirmed.
    • Patent apply is planned

    MDB-8117

    DRY-AMD

    Dry age-related macular degeneration

    Dry-AMD(Dry age-related macular degeneration)

    • Macular is the central tissue of the retina on the inside of the eye, like a film on a camera
    • Very important part of the eye that accounts for more than 90% of the visual acuity
    • It is called macular degeneration that denaturation occurs in this part, age-related macular degeneration is caused by aging.
    • Age-related macular degeneration is divided into dry and wet, 90% of macular degeneration is dry
    Causes
    • Caused by aging, smoking, genetic factors, nutritional factors, and cardiovascular disease.
    • It is rare for people under the age of 50, but more than three times the incidence rate at 75 or older compared to those aged 65 to 74.
    • The aging process causes wastes to accumulate between the choroid membrane and the retina, resulting in dry macular degeneration. Waste materials weaken macular tissue, resulting in neovascularization of the blood vessels, resulting in macular degeneration.
    Market / Research Status
    • Retinal disease (diabetic retinopathy, AMD) has the highest growth rate in the market worldwide (annual growth of 6%)
    • Retinal diseases market is expected to grow from $8.5 billion in 2015 to $17.2 billion in 2026.
    • No dry-AMD drug urrently
    • The association between NLRP3 inflammasome activation and retinal diseases (dry, wet, age-related macular degeneration) has been revealed and global pharmaceutical companies are developing drugs for AMD.
    Development Status
    • Mass production system for therapeutic raw materials is established, Collaboration with GLP institutions (efficacy and toxicity assessment)
    • Identification of equivalence of the animal model to the control group
    • Currently, the treatment of retinal disease (wet AMD) is injected directly into the eyeball. MDB-8117 is under development for oral use.
    • Domestic patent application (Application No. 10-2019-0056685)
    • Pre-clinical test planed in 2020

    MDB-8117

    AD

    Alzheimer’s disease

    Alzheimer’s disease

    • Degenerative cranial nervous system disease in which patient's memory and cognitive decline slowly
    • It was introduced in 1907 by a German psychiatrist, Alois Alzheimer's. Much research has been done since then.
    • Treatment still inadequate
    Causes
    • Accumulation of insoluble zombie cells or protein aggregates in the hippocampus and cerebral cortex
      - extracellular - amyloid beta protein, Aβ,
      - Intracellular- accumulation of a neurofibrillary tangle composed of hyperphosphorylated tau protein (neurofibrillary tangle, NFT)
    • Protein aggregation forms a fibrous 'amyloid' and accumulation in one part of the brain causes Alzheimer's disease.
    Market / Research Status
    • The Korean people recognized Alzheimer's disease as the highest priority disease in terms of medical expenditure (34.3%), patient family suffering (54.8%), cause of illness and treatment alternative (26.4%)
    • The global Alzheimer's disease drug market is expected to grow from $ 3.11 billion in 2015 to $ 12.61 billion in 2024, an annual average growth of 17%.
    • The number of treatments approved by the US FDA is five, but it is a way to alleviate symptoms or slightly slow the progression rate. Therefore, the demand for innovative new drugs is very high.
    • Global pharmaceutical companies are developing therapeutic agents based on amyloid hypothesis and Tau hypothesis (clinical study)
    • The association between NLRP3 inflammasome activation and Alzheimer's disease has been revealed and global pharmaceutical companies are working on the development of therapeutic drugs
    Development Status
    • Mass production system for therapeutic raw materials is established, collaboration with GLP institutions (efficacy and toxicity evaluation)
    • Identify efficacy in animal models equal to or greater than reference drug
    • Collaborative research with professional research institutes, participation in national projects
    • Domestic patent application (Application No. 10-2019-0070208)
    • Pre-clinical test planed in 2020

    MDB-8126

    MS

    Multiple sclerosis

    Multiple sclerosis

    • Chronic neuroimmune system disorders in the central nervous system, including the brain, spinal cord, and optic nerve
    • Disease that recurs and relapses clinically
    • Related diseases - neuromyelitis optica (NMO), acute disseminated encephalomyelitis, transverse myelitis, etc.
    Causes
    • The exact cause of the disease has yet to be elucidated, and it is estimated that the autoimmune reaction caused by the surrounding environment is a major cause of the onset in patients with genetic factors
    • Inflammatory cell infiltration of the central nervous system is presumed to be caused by an abnormality of the autoimmune system
    Market / Research Status
    • The market size is expected to increase to $ 24.8 billion by 2024
    • Drug development for Immunosuppressive drug is underway by global pharmaceutical companies
    • The association between NLRP3 inflammasome activation and multiple sclerosis has been revealed, and global pharmaceutical companies are working on the development of therapeutic drugs
    Development Status
    • In vitro efficacy evaluation studies
    • Completed derivation of lead material
    • Collaborative research with professional research institutes

    BTK inhibitor

    (BTK has a essential role for B cell(type of immune cell) differentiation

    • It is a member of the TEC family of tyrosine kinases, which affect the development of early B-cells and the activation of mature B-cells, regulatory factors regulating signal transduction and survival
    • It is activated through B-cell signaling through B-cell receptor (BCR) and plays a crucial role in signal transduction and development of B cells through regulation of various major signaling pathways in cells and induction of signal transduction essential for cell survival
    • When BTK is overexpressed by abnormal signal transduction by BCR in B cells, sub-molecules of the BCR signal transduction system Induced excessive phosphorylation in stages resulting in abnormal B cell proliferation and pathologic autoantibody formation. As a result, systemic lupus erythematosus, rheumatoid arthritis and cancer, autoimmune diseases, B cell malignant tumors and inflammatory diseases occur.

    MDB-8102

    RA

    Rheumatoid arthritis

    Rheumatoid arthritis

    • Chronic inflammatory disease with inflammation in various joints, including hands and wrists, feet and ankles
    • The exact cause of the disease has yet to be elucidated but, autoimmunity is the main cause
    Causes
    • As the synovial membrane surrounding the joint is inflamed, monocytes, lymphocytes, and other white blood cells are gathered into the joints. As a result, the joint fluid is increased and the joints are swollen and painful
    Development Status
    • Derivation of hit material with inhibitory effect on BTK activation
    • Domestic patent application (Application No. 10-2019-0052360)
    • Plan to collaborate with professional research institutes for efficacy test

    MDB-8129

    LN

    Lupus nephritis

    Lupus nephritis

    • Collagen vascular diseases caused by systemic lupus erythematosus, connective tissue disorders invading the kidney
    Causes
    • Autoimmune disease in which the immune system attacks the human body due to an abnormality in the immune system.
    Development Status
    • Derivation of hit material with inhibitory effect on BTK activation
    • Domestic patent application (Application No. 10-2019-0052360)
    • Plan to collaborate with professional research institutes for efficacy test

    MDB-8103

    Psoriasis

    Psoriasis

    Psoriasis

    • Chronic skin disease, red-colored papules covered with silvery white scales (convex spots), and plate-like rashes occur repeatedly
    Causes
    • The exact cause of the disease has yet to be elucidated
    • The activity of T cells, the immune cells in the skin, is increased, and the secreted immune substances stimulate the keratinocytes of the skin, resulting in excessive proliferation of keratinocytes and inflammation
    Market / Research Status
    • In the United States, about 2.6% of the total population is affected, of which 1.5 million are seriously ill, about 200,000 new cases occur annually
    • Estimated $ 2 billion annually for treatment
    • Global pharmaceutical companies are developing biotherapeutics using T cells and therapeutic agents targeting cytokines.
    Development Status
    • Collaborative research with professional research institutes (study of efficacy and mode of action)
    • Candidate Derivation
    • Plan for patent application and pre-clinical test in 2019

    MDB-8112

    Cancer

    Cancer

    Cancer

    • Disorder in which cells fail to precisely regulate the cell lifecycle
    • Cancer transitions to the periphery and interferes with organic regulation of life
    Causes
    • Caused by a variety of factors such as mutations, reactive oxygen species, and external stimuli
    Market / Research Status
    • Second highest cause of death worldwide
    • 10 million new cases occur annually
    • Global anticancer drug market is estimated at $ 83.1 billion, an increase of 13% annually, expected up to $ 190 billion in 2022
    • Development of cancer immunotherapy to attack cancer cells by enhancing the immune system of the human body is actively in progress
    Development Status
    • in vitro efficacy assessment and mode of action studies
    • Hit material optimization